(GILD) – Analyzing Gilead Sciences’s Short Interest
Gilead Sciences’s (NYSE:GILD) short percent of float has risen 6.41% since its last report. The company recently reported…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Secretly Monitor But Don’t Talk About Yet
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
A Look Into Gilead Sciences Inc’s Price Over Earnings
Looking into the current session, Gilead Sciences Inc. (NASDAQ:GILD) shares are trading at $79.75, after a 1.03% increase.…
Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today?
Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK) for approximately $21.25 million,
RedHill’s Investigational COVID-19 Drugs Combined With Gilead’s Show Effect Against Ebola
RedHill Biopharma Ltd (NASDAQ: RDHL) says opaganib and RHB-107 (upamostat) demonstrated robust synergistic effects when combined individually with Gilead Sciences Inc (NASDAQ: GILD) Veklury (remdesivir) i
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the
(GILD) – Analyzing Gilead Sciences’s Short Interest
Gilead Sciences’s (NYSE:GILD) short percent of float has fallen 4.29% since its last report. The company recently reported…
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion in